<DOC>
	<DOCNO>NCT01463293</DOCNO>
	<brief_summary>This study investigate effect 4-week probiotic supplementation whole gut transit time gastrointestinal symptom adult functional constipation .</brief_summary>
	<brief_title>B. Lactis HN019 Functional Constipation</brief_title>
	<detailed_description>This prospective , double-blind , randomize , placebo-controlled clinical trial investigate effect 4-week B. lactis HN019 supplementation whole gut transit time gastrointestinal symptom adult functional constipation . Participants meet study entry criterion enter 2-week run-in period . Following successful completion run-in period , subject randomize 4-week supplementation B. lactis HN019 ( 10 billion cfu ) , B. lactis HN019 ( 1 billion cfu ) , placebo . The primary outcome whole gut transit time evaluate abdominal x-rays day 0 28 . Secondary outcome include IBS-specific questionnaire ( administer day 0 28 ) ; abdominal pain severity , bowel movement frequency , stool consistency , adverse event ( evaluate daily throughout study ) ; overall product satisfaction ( evaluate day 28 ) . Physical activity questionnaires 24-hour food recall complete periodically trial .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<criteria>Age 18 70 year Body mass index 18.5 34.9 kg/m2 Selfreported unsatisfactory defecation due infrequent stool and/or difficult stool passage , include least one following : symptom strain , difficulty expel stool , sense incomplete evacuation , hard lumpy stool , prolong time stool , need manual maneuver pass stool . Estimated stool consistency &lt; 4.0 BSSF ( selfreported screening ) within past month prior enrollment . Ability participant ( investigator 's opinion ) comprehend full nature purpose study include possible risk side effect Consent study willing comply study product method Major gastrointestinal complication ( e.g . Crohn 's disease , ulcer ) Prior abdominal surgery , opinion investigator , may present risk subject confound study result Clinically significant underlying systemic illness may preclude subject 's ability complete trial may confound study outcome ( e.g . bowel cancer , prostate cancer , terminal illness ) Daily consumption probiotic , prebiotics , ferment milk , and/or yogurt within 2 week screen throughout trial provide study product Nonlaxative constipation medication use within 2 week screen , laxative use within 48 hour screen ( rescue medication allow intolerable symptom study ) Daily use anticholinergic agent , opioid analgesic , calcium supplement , calciumchannel blocker , NSAIDs Anticipated major dietary exercise change study Systemic steroid use Eating disorder Contraindication dairy product ( e.g. , intolerance lactose substance study product ) History alcohol , drug , medication abuse Pregnant lactate female , pregnancy plan study period Participation another study investigational product within 30 day screen Investigator believe participant may uncooperative and/or noncompliant therefore participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>constipation</keyword>
	<keyword>probiotic</keyword>
	<keyword>functional constipation</keyword>
	<keyword>IBS-C</keyword>
</DOC>